BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19425054)

  • 1. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
    Cappello P; Tomaino B; Chiarle R; Ceruti P; Novarino A; Castagnoli C; Migliorini P; Perconti G; Giallongo A; Milella M; Monsurrò V; Barbi S; Scarpa A; Nisticò P; Giovarelli M; Novelli F
    Int J Cancer; 2009 Aug; 125(3):639-48. PubMed ID: 19425054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated alpha-enolase induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation.
    Capello M; Caorsi C; Bogantes Hernandez PJ; Dametto E; Bertinetto FE; Magistroni P; Rendine S; Amoroso A; Novelli F
    Immunol Lett; 2015 Sep; 167(1):11-6. PubMed ID: 26096821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody signature in human ductal pancreatic adenocarcinoma.
    Tomaino B; Cappello P; Capello M; Fredolini C; Ponzetto A; Novarino A; Ciuffreda L; Bertetto O; De Angelis C; Gaia E; Salacone P; Milella M; Nisticò P; Alessio M; Chiarle R; Giuffrida MG; Giovarelli M; Novelli F
    J Proteome Res; 2007 Oct; 6(10):4025-31. PubMed ID: 17824682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells.
    Zhou W; Capello M; Fredolini C; Piemonti L; Liotta LA; Novelli F; Petricoin EF
    J Proteome Res; 2010 Jun; 9(6):2929-36. PubMed ID: 20433201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.
    Principe M; Ceruti P; Shih NY; Chattaragada MS; Rolla S; Conti L; Bestagno M; Zentilin L; Yang SH; Migliorini P; Cappello P; Burrone O; Novelli F
    Oncotarget; 2015 May; 6(13):11098-113. PubMed ID: 25860938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.
    Tomaino B; Cappello P; Capello M; Fredolini C; Sperduti I; Migliorini P; Salacone P; Novarino A; Giacobino A; Ciuffreda L; Alessio M; Nisticò P; Scarpa A; Pederzoli P; Zhou W; Petricoin Iii EF; Liotta LA; Giovarelli M; Milella M; Novelli F
    J Proteome Res; 2011 Jan; 10(1):105-12. PubMed ID: 20455595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients.
    Schmitz-Winnenthal FH; Volk C; Z'graggen K; Galindo L; Nummer D; Ziouta Y; Bucur M; Weitz J; Schirrmacher V; Büchler MW; Beckhove P
    Cancer Res; 2005 Nov; 65(21):10079-87. PubMed ID: 16267034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
    Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
    Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.
    Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F
    Gastroenterology; 2013 May; 144(5):1098-106. PubMed ID: 23333712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
    Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
    Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response.
    Di Modugno F; Bronzi G; Scanlan MJ; Del Bello D; Cascioli S; Venturo I; Botti C; Nicotra MR; Mottolese M; Natali PG; Santoni A; Jager E; Nisticò P
    Int J Cancer; 2004 May; 109(6):909-18. PubMed ID: 15027125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma.
    Niccolai E; Cappello P; Taddei A; Ricci F; D'Elios MM; Benagiano M; Bechi P; Bencini L; Ringressi MN; Coratti A; Cianchi F; Bonello L; Di Celle PF; Prisco D; Novelli F; Amedei A
    Int J Oncol; 2016 Jul; 49(1):393-401. PubMed ID: 27210467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model.
    Schmidt T; Ziske C; Märten A; Endres S; Tiemann K; Schmitz V; Gorschlüter M; Schneider C; Sauerbruch T; Schmidt-Wolf IG
    Cancer Res; 2003 Dec; 63(24):8962-7. PubMed ID: 14695214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of c-kit expression in pancreatic adenocarcinoma: a novel stem cell marker responsible for the progression of the disease.
    Amsterdam A; Raanan C; Polin N; Melzer E; Givol D; Schreiber L
    Acta Histochem; 2014 Jan; 116(1):197-203. PubMed ID: 23978330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters.
    Wu W; Zhang J; Zhou L; You L; Zhao Y; Li J
    Sci China Life Sci; 2012 Sep; 55(9):747-52. PubMed ID: 23015122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducing a humoral immune response to pancreatic cancer antigen.
    Seifert M; Seifert G; Wolff-Vorbeck G; Langenmair E; Hopt UT; Wittel UA
    Cell Immunol; 2016 Dec; 310():150-155. PubMed ID: 27663207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
    Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
    Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pentamer guided HLA-restricted epitope identification for mucoprotein 4 antigen of pancreatic ductal adenocarcinoma].
    Gao WT; Zhang JJ; Zhu Y; Wei JS; Meng K; Chen JM; Wu JL; Miao Y
    Zhonghua Wai Ke Za Zhi; 2010 Sep; 48(18):1416-24. PubMed ID: 21092580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.